Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
1.1 Inclusion Criteria for Double-Blind and Recurrence~1. Males or non-pregnant females, aged ≥ 18 to ≤ 75 years.~2. Symptomatic internal hemorrhoids, Grades I-III by direct anoscopic visualization (anoscopic visualization not required if Grade determined by colonoscopy within 28 days prior to Day 1).~3. Bleeding from hemorrhoids for two consecutive days prior to randomization (Day 1).~   • For females experiencing menses, on the two days prior to randomization they must confirm that blood is from the anus and not from their menses by gently inserting a cotton swab into the anus after attempting a bowel movement; and they must see blood on the cotton swab for the two consecutive days prior to randomization to meet the inclusion criteria.~4. Itching OR pain for two consecutive days prior to randomization (Day 1).~5. Able to attempt bowel movements daily (defined as trying to have a bowel movement while sitting on the toilet for at least a few minutes, at least once daily, whether or not you feel the need to have a bowel movement that day).~6. Body mass index of ≥ 18.5 to ≤ 36 kg/m2.~7. Female of non-childbearing potential, including any female who: a) has had a hysterectomy, b) has had a bilateral oophorectomy, c) has had a bilateral tubal ligation or d) is post menopausal (demonstration of total cessation of menses for ≥ 1 year from the date of the screening visit).~8. Females of child bearing potential who agree to use two forms of contraception, one of which must be a barrier method, during the full duration of the study.~9. Able to communicate adequately with the investigator and to comply with the requirements for the entire study.~10. Capable of using the IVRS and adequately communicate comprehension of IVRS questions to the investigator.~11. Capable of and freely willing to provide written informed consent prior to participating in the study.~1. 1.2 Exclusion Criteria for Double-Blind and Recurrence~1. Grade IV internal hemorrhoids.~2. Age ≥ 40 years, with no complete colon evaluation within three years.~3. Age \< 40 years, with no sigmoidoscopy or complete colon evaluation within three years.~4. Age \< 40 years, with any of the following and no complete colon evaluation within two years; or age ≥ 40 years, with any of the following and no complete colon evaluation within one year:~   * History of adenomatous polyps.~  * Family history of either colorectal cancer or colorectal adenomas diagnosed in a first-degree relative before age 60.~  * Family history or genetic testing indicating the presence of one of two hereditary syndromes.~5. Malignancy within 5 years prior to Day 1(with the exception of treated basal cell/squamous cell carcinoma of the skin).~6. History of inflammatory bowel disease.~7. History of irritable bowel syndrome with constipation or diarrhea.~8. Previous surgical or instrumental treatment of internal hemorrhoids.~9. Clinical evidence or history of fecal incontinence.~10. Current thrombosed internal or external hemorrhoid(s).~11. Clinical evidence or history of anal fissure.~12. Clinical evidence or history of anal fistula.~13. AST/ALT \> 3x ULN.~14. Hemoglobin \< 10.0 g/dL.~15. Selective serotonin reuptake inhibitors within 28 days prior to Day 1.~16. Tamoxifen within 28 days prior to Day 1.~17. Laxatives (unless maintained on a stable dose of the medication for ≥ 60 days prior to Day 1).~18. Anticoagulants (e.g., coumadin, heparinoids, dabigatran) within 90 days prior to Day 1.~19. Anti-platelet agents or low dose aspirin (unless maintained on the medication for ≥ 90 days prior to Day 1).~20. Over the counter or prescription anti-hemorrhoid agents (including herbal supplements) within 14 days prior to Day 1.~21. Topical anesthetics within 14 days prior to Day 1.~22. Chronic use of analgesics (e.g., opioids, acetaminophen, aspirin, NSAIDS, cox-2 inhibitors, etc).~23. Any investigational agents within 28 days prior to Day 1 (with the exception of iferanserin for recurrence).~24. Anti-TNF agents within 6 months prior to Day 1.~25. Oral or parenteral steroids within 28 days prior to Day 1.~26. Use of anal, intra-anal, or intra-rectal steroids within 28 days prior to Day 1.~27. Expected to have a planned interventional and/or surgical procedure that requires hospitalization, colonoscopy, or sigmoidoscopy (colonoscopy or sigmoidoscopy during the screening period is acceptable).~28. Following concomitant disease state:~    * Clinical evidence or history of significant cardiovascular disease including arrhythmias, clinically significant ECG abnormalities, myocardial infarction, stroke, congestive heart failure (greater than class II), and valve disease or abnormalities.~   * Asthma currently requiring treatment (with the exception of infrequent use of rescue inhaler).~   * Clinical evidence or history of chronic renal failure (greater than Stage III).~   * Clinical evidence or history of gastric ulcer, duodenal ulcer, or pancreatitis.~   * Clinical evidence or history of hematological disease.~   * Clinical evidence or history of neurological disease.~   * Acute infection currently requiring treatment.~   * Clinical evidence or history of chronic infectious disease.~29. Major organ transplant.~30. Any disease or prior surgery that may interfere with the subject successfully completing the study.~31. History of any prior anal or rectal surgery (hemorrhoid banding with the 5 years of Day 1).~32. Psychosis, schizophrenia, mania, depressive disorders, history of suicide attempt or suicidal ideation, or any other psychiatric illness (with the exception of intermittent anxiety).~33. Known sensitivity to investigational product(s) or class of investigational product(s).~34. Drug or alcohol abuse within 12 months of Day 1.~35. Currently using narcotic(s) chronically.~36. Breast-feeding females.~37. Females on their menstrual cycle who cannot discern whether the bleeding is rectal bleeding or vaginal bleeding from menstruation.~38. Employees, family members, or students of the investigator or clinical site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Iferanserin (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None
- Iferanserin + Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy